Search Results
CRB-401: is CAR T-cell therapy the future of multiple myeloma treatment?
CAR T-cell therapy for refractory multiple myeloma
CRB-401 18-month follow-up: influence of T-cell profile on outcome of ide-cel treatment in myeloma
Updated Results of the Idecabtagene Vicleucel (ide-cel bb2121) CRB-401 Trial in RR Multiple Myeloma
CAR T-cells: targeting BCMA
CRB-401: ide-cel for R/R multiple myeloma
ide-cel; bb2121, a BCMA-targeted CAR T-cell therapy, in patients with RRMM: Initial KarMMa results
The future of immunotherapies for multiple myeloma
Dr. Madduri on Eligibility for CAR T-Cell Therapy in Myeloma
Can a patient use a different CAR-T target after receiving BCMA directed therapy?
Early MRD negativity predicts depth of response to CAR T-cells in R/R MM
Value of MRD status one month after CAR-T therapy in patients with multiple myeloma
